uveal melanoma
Oncology · 2023–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tebentafusp Treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma. | Sep 2023 | Not recommended | 10 individuals Skin Cancer Advocacy Network · Rare Cancers Australia · Australasian Ocular Melanoma Alliance · Melanoma Patients Australia · Ocumel Australia · Medical Oncology Group |
Who spoke
Skin Cancer Advocacy Network · Rare Cancers Australia · Australasian Ocular Melanoma Alliance · Melanoma Patients Australia · Ocumel Australia · Medical Oncology Group
What the PBS pays
$18M in government benefit over 2024–25, across 997 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tebentafusp | $17.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tebentafuspTebentafusp for treating advanced uveal melanoma | TA1027 | recommended restricted | 2025-01 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.